Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 27, 2026, 9:30 AM ET
Oncolytics Biotech reported updated GOBLET Cohort 4 data showing approximately 15 months median duration of response for pelareorep plus atezolizumab in second-line or later squamous cell anal cancer.
Nasdaq: $ONCYREO 033 randomized evidenceGOBLET follow-upFinancing and listing risk
ONCY Stock Hub: Oncolytics News, REO 033 and the Funding Test
Randomized colorectal evidence must arrive with adequate capital behind it. The potential year-end REO 033 interim is conditional on evaluable patients. October GOBLET anal-cancer follow-up is a separate small-cohort evidence stream; historical cash and financing claims remain central. The October 29 regular-session close was $0.4277 (-3.15% versus October 28).
Full research report · PDF
Oncolytics Biotech ($ONCY), research as of October 20, 2026
15 pages covering the existing long-form Oncolytics hub labeled with an October 20, 2026 news update, including the separately dated October 27 GOBLET update already present in that original content. Dates are preserved rather than treated as a uniform October 20 snapshot. This is a dated research snapshot; the hub follows later developments. For personal use only: redistribution prohibited.
Next existing clinical window · conditional
Potential year-end 2026 · REO 033 Part A interim
The September 28 plan links the potential interim to the number of evaluable patients enrolled by the end of October. It does not guarantee a year-end result or an agreed pivotal expansion. Source: company announcement
The October 27 GOBLET update reports anal-cancer durability, not the randomized REO 033 colorectal outcome. Nasdaq compliance has a separate January 19, 2027 deadline; notices and conditional additional time are distinct from delisting. Source: SEC
ONCY stock at a glance
Close · October 29, 2026
$0.4277
Regular-session close; -3.15% versus $0.4416 on October 28.
REO 033 interim window
Year-end 2026
September 28 plan; depends on evaluable patients by end-October · Source
Nasdaq bid compliance deadline
January 19, 2027
Initial period in the July filing, distinct from completed delisting; additional time is conditional. Source: SEC
Where Oncolytics Biotech stands now
June cash and equivalents were $4.115M, with historical H1 operating-plus-capital use averaging $2.573M per month. Those balances and calculations exclude later financing and spending. The quarterly filing includes going-concern uncertainty. The $75M ATM ceiling is equity-sale capacity, not a funded credit line. Source: SEC
Patient evaluability, controlled outcomes and financing cannot be separated.
The randomized study fails to reproduce the earlier signals, the update slips because too few patients are evaluable, or treatment burden prevents a useful benefit. A historical randomized colorectal study illustrates why response rate and longer disease control must be considered separately: adding pelareorep increased response but produced worse progression-free survival in that different first-line combination. That result does not determine REO 033, but it prevents treating tumor shrinkage as sufficient proof of value. Source
The constructive case
The favorable scenario requires REO 033 to demonstrate a credible improvement over its concurrent control and the company to finance a pivotal expansion on workable terms. The September 28, 2026 update says substantially all planned sites are active and several patients are enrolled. Management expects an interim update by year-end, conditional on the number of evaluable patients enrolled by the end of October. A favorable outcome requires useful comparative data, sufficient follow-up and tolerability that allows patients to receive the treatment combination. A promotional response-rate headline alone would not satisfy that test. Source
The cautious case
The randomized study fails to reproduce the earlier signals, the update slips because too few patients are evaluable, or treatment burden prevents a useful benefit. A historical randomized colorectal study illustrates why response rate and longer disease control must be considered separately: adding pelareorep increased response but produced worse progression-free survival in that different first-line combination. That result does not determine REO 033, but it prevents treating tumor shrinkage as sufficient proof of value. Source
Latest Oncolytics Biotech news
October 27, 2026
GOBLET anal-cancer update reports durability
The company reports approximately 15-month median response duration and overall-survival median not reached for pelareorep plus atezolizumab. Its historical monotherapy comparison is from a separate study, not randomized head-to-head evidence. Cohort size is not stated in the release; efficacy estimates are internally calculated. Further registrational studies remain plans subject to FDA agreement.
October 20, 2026
ESMO poster describes REO 033 trial design
The randomized Phase 2 trial plans 30 patients per arm and uses objective response as its primary endpoint. The trial-in-progress poster contains design information rather than new results; the possible pivotal expansion remains conditional.
October 14, 2026
GOBLET reporting and grant windows described
The company guided final Cohort 4 results to Q4 and initial Cohort 5 pancreatic results to H1 2027, with possible extension as follow-up continues. A final PanCAN payment was expected later in the quarter after specified activities; no amount was disclosed.
October 12, 2026
Patent strategy includes conditional future protection
Issued and pending method-of-use and next-generation composition claims may extend protection. The late-2040s horizon depends on patents issuing and their granted claims; prioritized review does not assure allowance.
September 29, 2026
Liver-cancer publication is preclinical
The study supports immune activity in a model. The company says it is not pursuing a liver indication at this time; the publication is not a human efficacy readout.
September 28, 2026
REO 033 enrollment and conditional interim window
The company reports active sites and enrollment progress. Potential year-end interim timing depends on evaluable patients by end-October; Part A would inform a possible pivotal expansion.
ONCY stock catalysts and operating watchpoints
- Potential year-end 2026 — REO 033 Part A interim, conditional on evaluable patients enrolled by end-October. Conditional company window
- October 27, 2026 · completed update — GOBLET Cohort 4 durability update already reported; distinct from the randomized colorectal trial. Past clinical update
- H1 2027 — Initial GOBLET Cohort 5 pancreatic results guided October 14; follow-up may extend timing. Company window
- January 19, 2027 — Initial Nasdaq bid-price compliance deadline. Filed compliance deadline
Cash and monthly consumption: the dated balance is already a warning
At June 30, 2026, cash and equivalents were $4.115 million, down from $5.202 million at December 31, 2025. Operating activities used $15.431 million in the first half, with another $0.006 million spent on equipment. The calculated combined monthly consumption was $2.573 million, versus approximately $2.572 million for operating cash use alone. The company was financing development on a scale much larger than its remaining quarter-end cash balance. Source
Dividing June cash by the historical operating-plus-capex pace gives approximately 1.6 months. That is a static illustration, not an October cash estimate, a date of insolvency or a forecast that subsequent financing did not occur. The same filing reports additional ATM sales after June. The actual current balance depends on those receipts, later issuance and intervening spending. Source
ATM financing and the actual increase in shares
The first half of 2026 brought $14.385 million of net ATM financing through 15,305,933 shares. That was less than the $15.437 million combined operating and equipment outflow. Financing largely replenished expenditure rather than creating a large reserve. It also increased the number of shares over which any future successful product value would be spread. Source
The previous BTIG arrangement ended in March. The new Jefferies agreement established April 6, 2026 permits up to $75 million of gross sales. During the June quarter, the company sold 7,859,359 shares under that arrangement for $7.152 million gross and $6.771 million net, at an average price of $0.91. Between July 1 and August 10 it sold another 2,322,984 shares for $1.890 million gross and $1.834 million net, averaging $0.81. Source
Merlintrader Health Score · $ONCY
2.05out of 5
Assessed October 4, 2026. Weighted calculation: 1.5×30% + 3.0×30% + 1.5×20% + 2.0×10% + 2.0×10% = 2.05. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- Financial balances retain their reporting dates and are not current cash.
- Milestone guidance is conditional; execution, collection and per-share outcomes remain separate tests.
ONCY Stock FAQ: Oncolytics Biotech Questions Answered
Is the year-end REO 033 update guaranteed?
No. The September 28, 2026 announcement conditions management’s expectation on the number of evaluable patients enrolled by the end of October. Part A plans approximately 60 patients, but an interim may use a smaller assessed population. The actual denominator and follow-up will determine how much can be concluded. Source
Has the FDA approved pelareorep or the final pivotal program?
No drug approval is announced. The August 18, 2026 release describes written feedback on a potential Part B and a possible accelerated route using response and duration, with progression-free survival supporting potential full approval. The agency suggested an End-of-Phase meeting to reach final agreement on key elements. Source
Does 1.6 months mean the company ran out of cash?
No. That static calculation divides June 30 cash of $4.115M by the first-half operating-plus-capex average of $2.573M monthly. It excludes later financing and spending. The filing also reports $1.834M net ATM proceeds from July 1 through August 10, while still warning that resources do not fund twelve months of planned operations. Source
Is the $75 million ATM a funded credit line?
No. It is the gross offering ceiling of the April 6, 2026 Jefferies sales agreement. Cash arrives only when shares are sold, after costs, and actual use changes the share count. The ceiling and unused capacity are not the same as money already received or committed by a lender. Source
Do higher response rates necessarily mean longer disease control?
No. The 2018 IND.210 colorectal study randomized 103 patients and reported increased response but shorter progression-free survival, seven versus nine months, p=0.046. It used a different first-line combination from REO 033. The result does not predict the new trial, but illustrates why response, duration and tolerability must be read together. Source
Primary sources
- Oncolytics — Form 10-Q, June 30, 2026, filed August 12; financial figures in USD
- Oncolytics — 2025 annual report, filed March 30, 2026; March 23 beneficial ownership table
- Oncolytics — REO 033 enrollment and conditional year-end interim update, September 28, 2026
- Oncolytics — preclinical liver cancer publication, September 29, 2026
- Oncolytics — preclinical pan-RAS combination results, September 10, 2026
- Oncolytics — FDA feedback on potential REO 033 pivotal expansion, August 18, 2026
- Goel et al. — pelareorep Phase 1 colorectal pharmacodynamics and clinical results, 2020
- Jonker et al. — randomized IND.210 colorectal trial, 2018; response and progression-free survival
- Clark et al. — randomized BRACELET-01 breast cancer results, 2025
- Oncolytics — Nasdaq July 20, 2026 bid-price notice and January 19, 2027 compliance deadline; filed July 24
- Jared Kelly — June 1, 2026 option award, Form 4 filed June 3
- Kirk Look — June 1, 2026 option award, Form 4 filed June 3
- Oncolytics — GOBLET clinical data timing and final PanCAN grant payment, October 14, 2026 (Form 8-K, Exhibit 99.1)
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ONCY or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
